Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 5, 2026Cancer Research

Anti-ROR2 Therapies Target Cancer Stem Cells in Triple-Negative Breast Cancer

View Full Paper
Ask AI
Bookmark
Share

Authors

EGEmanuela M. GhiaCHCan HuangRSRebecca Shatsky

Discussion

Loading...

Member takes

Overview

Experimental therapies target cancer stem cells in triple-negative breast cancer, suggesting new treatment strategies.

Key Points

  • This research aims to investigate whether targeting ROR2 in triple-negative breast cancer stem cells can reverse drug resistance and persistence.
  • Used patient-derived xenografts in NSG mice to compare TNBC tissues and PDX.
  • Applied oligonucleotide-barcoded antibodies and single-cell RNA-seq for analysis.
  • Developed a high-affinity monoclonal antibody specific for human ROR2.
  • Tested the effects of h6E6 monoclonal antibody and APR-246 on cancer cell sensitivity.
  • ROR2+ TNBC cells demonstrated increased stemness, EMT, and upregulated signaling pathways.
  • h6E6 treatment significantly enhanced the sensitivity of TNBC PDX cells to APR-246.
  • In vivo h6E6 treatment led to reduced cancer stemness and EMT gene expression.
  • The combined treatment effectively decreased therapy resistance markers and increased sensitivity to drugs.

Cite This Study

Ghia et al. (2026) studied this question.

synapsesocial.com/papers/69d1fd73a79560c99a0a374chttps://doi.org/10.1158/1538-7445.am2026-4038
View Full Paper
Ask AI
Bookmark
Share